First-in-Human trial launches for experimental CAR-T treatment targeting tough kidney cancer
NCT ID NCT07500805
Summary
This is an early, first-in-human study to test the safety and initial effectiveness of an experimental cell therapy called UCL70805F for patients with advanced kidney cancer. The therapy involves collecting and genetically modifying a patient's own immune cells to target a specific protein (CD70) found on their cancer cells. The study will enroll a small group of patients whose cancer has progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD70-POSITIVE ADVANCED RENAL CLEAR CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.